No Detail Found!

Iloperidone works in synergy with temozolomide to limit the proliferation of glioblastoma cells

Author(s)
Sahar Mubeen Department of Anatomy, Dow International Medical College, Dow University of Health Sciences, Karachi, Pakistan
Iffat Raza Department of Anatomy, Karachi Institute of Medical Sciences, Karachi, Pakistan
Ather Enam Department of Surgery, Dow University of Health Sciences, Karachi, Pakistan
Badruddin Ujjan Department of Surgery, Dow University of Health Sciences, Karachi, Pakistan
Muhammad Sameer Department of Surgery, Dow University of Health Sciences, Karachi, Pakistan
Lubna Khan Department of Biochemistry, Dow International Medical College, Dow University of Health Sciences, Karachi, Pakistan
Farina Hanif Department of Biochemistry, Dow International Medical College, Dow University of Health Sciences, Karachi, Pakistan
Abstract
The ability of GBM to infiltrate, multiply, and recur makes it the most deadly and aggressive brain tumor. Additionally, it becomes resistant to medications and radioactive materials, and the grim outlook just makes matters worse. Antipsychotics have the potential to treat GBM and have a propensity to break through resistance. In comparison to other antipsychotics, iloperidone has fewer side effects. Its ability to be repurposed against GBM is still being researched. The purpose of the current study is to determine whether the FDA-approved anti-psychotic drug iloperidone may be used to treat GBM either alone or in combination with the medication temozolamide. Under typical circumstances, the U87 glioma cell line was grown. For 48 hours, the cells were exposed to iloperidone and temozolamide at varying concentrations (10uM to 90uM), both alone and in combination. MTT was used to examine how iloperidone alone and in combination with the common medication temozolamide inhibited growth. The drug interaction coefficient was determined, and doses that demonstrated synergistic activity were then used in the wound healing assay. Image J was used to analyse the wound`s area. The development of U87 cells was greatly slowed down by both iloperidone and temozolomide. The result, nevertheless, was dose independent. Additionally, a synergistic interaction between iloperidone 60 uM and temozolamide 60 uM greatly reduced U87 cell proliferation. Iloperidine and TMZ both prevented U87 from migrating. When U87 cells` migration was inhibited, the synergism was not seen. Iloperidone, an atypical antipsychotic, combined with temozolomide to synergistically decrease the proliferation of U87 cells.
Publication Details
Page(s)
DOI DOI not available
Published Journal: Abstract Book on 9th Annual Neuroscience Conference (ANC-23) August 12-13, 2023 , Volume: 0, Issue: 0, Year: 2023

Request the full text from PASTIC

0

Citations

0

Downloads

237

Views